J Rheum Dis.  2012 Feb;19(1):51-54. 10.4078/jrd.2012.19.1.51.

A Case of Refractory SAPHO Syndrome Treated with Etanercept

• Kim YJ
• Bae SI
• Choi SJ
• Lee YH
• Ji JD
• Song GG

• KMID: 2223121
• DOI: http://doi.org/10.4078/jrd.2012.19.1.51

Abstract

SAPHO syndrome, which has different skin changes and osteoarticular inflammation, is an acronym that stands for synovitis, acne, pustulosis, hyperostosis, and osteitis. Treatment of SAPHO syndrome includes non-steroidal anti-inflammatory drugs (NSAIDs), anti-rheumatic drugs, such as colchicines, corticosteroids and bisphosphonates, and disease-modifying agents. However, the treatment of SAPHO syndrome is controversial because it is a new clinical entity with unclear etiopathogenesis and inadequate clinical studies. We report a case with refractory SAPHO syndrome, which was successfully treated with a tumor necrosis factor (TNF)-alpha blocker.

Keyword

SAPHO syndrome; Treatment; TNF-alpha blocker

MeSH Terms

Acne Vulgaris
Acquired Hyperostosis Syndrome
Adrenal Cortex Hormones
Antirheumatic Agents
Diphosphonates
Hyperostosis
Immunoglobulin G
Inflammation
Osteitis
Receptors, Tumor Necrosis Factor
Skin
Synovitis
Tumor Necrosis Factor-alpha
Etanercept
Adrenal Cortex Hormones
Antirheumatic Agents
Diphosphonates
Immunoglobulin G
Receptors, Tumor Necrosis Factor
Tumor Necrosis Factor-alpha